ImmunoPET: concept, design, and applications

W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

[HTML][HTML] Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade

G Crișan, NS Moldovean-Cioroianu… - International Journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …

[HTML][HTML] Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

N Dammes, D Peer - Theranostics, 2020 - ncbi.nlm.nih.gov
Molecular imaging modalities hold great potential as less invasive techniques for diagnosis
and management of various diseases. Molecular imaging combines imaging agents with …

[HTML][HTML] Current Perspectives on 89Zr-PET Imaging

JK Yoon, BN Park, EK Ryu, YS An, SJ Lee - International Journal of …, 2020 - mdpi.com
89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …

[HTML][HTML] Radiolabeled antibodies for cancer imaging and therapy

S Parakh, ST Lee, HK Gan, AM Scott - Cancers, 2022 - mdpi.com
Simple Summary Monoclonal antibodies (mAbs) have the ability to specifically target tumor-
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …

CD38-targeted immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging

GA Ulaner, NB Sobol, JA O'Donoghue, AS Kirov… - Radiology, 2020 - pubs.rsna.org
Background Current measurements of multiple myeloma disease burden are suboptimal.
Daratumumab is a monoclonal antibody that targets CD38, an antigen expressed on nearly …

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer

F Sanchez-Vega, JF Hechtman, P Castel, GY Ku… - Cancer discovery, 2019 - AACR
The anti-HER2 antibody trastuzumab is standard care for advanced esophagogastric (EG)
cancer with ERBB2 (HER2) amplification or overexpression, but intrinsic and acquired …

First-in-human human epidermal growth factor receptor 2–targeted imaging using 89Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast …

GA Ulaner, SK Lyashchenko, C Riedl… - Journal of Nuclear …, 2018 - Soc Nuclear Med
In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of
89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)–targeted …

[HTML][HTML] Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy

PMR Pereira, SK Sharma, LM Carter… - Nature …, 2018 - nature.com
Human epidermal growth factor receptor 2 (HER2) gene amplification and/or protein
overexpression in tumors is a prerequisite for initiation of trastuzumab therapy. Although …

[HTML][HTML] ImmunoPET: antibody-based PET imaging in solid tumors

R Manafi-Farid, B Ataeinia, S Ranjbar… - Frontiers in …, 2022 - frontiersin.org
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …